Skip to main content
OpenTrials
Completed

NCT Number: NCT07740187

A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility

This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal.

The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Female Infertility Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Fertility Genital Diseases Genital Diseases, Female Hormonal Imbalance Infertility Infertility, Female Ovarian Reserve Reproductive Health Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be female.
  • Be aged 18-45.
  • In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue
  • Bloating
  • Breast tenderness
  • Irritability or mood swings.
  • Currently trying to conceive.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Not planning on introducing any products or any new forms of prescription medication or supplements that target female fertility for the study duration.
  • Has a regular menstrual cycle between 21 and 35 days in length and is able to predict the dates of their upcoming periods.
  • Resides in the United States.
  • Not currently partaking in another research study and will not be partaking in any other research study for the next three menstrual cycles and at any point during this study's duration.
  • Willing to avoid all other prenatal vitamins for the duration of this study.

Exclusion criteria

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are currently pregnant or breastfeeding.
  • Anyone taking anticoagulant or "blood thinning" medication.
  • Anyone taking bisphosphonates or other prescription medications for osteoporosis.
  • Anyone taking chemotherapy medication.
  • Anyone diagnosed with hemochromatosis or elevated iron levels.
  • Anyone who drinks heavily (i.e. eight or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
  • Anyone unwilling to follow the study protocol.
  • Anyone with a history of substance abuse.
  • Anyone who is currently a smoker or has been a smoker in the past three months.
  • Anyone who has stopped using hormonal birth control less than six months prior to starting the study.
  • Anyone previously diagnosed with premenstrual dysphoric disorder (PMDD), endometriosis, or any cancer of the reproductive system.
  • Anyone who is peri- or post-menopausal.

Treatment and study plan

WeNatal For Her Supplement

Dietary Supplement

All 40 participants take three capsules of the WeNatal For Her supplement daily in the morning with their first meal for three menstrual cycles.

Primary outcomes

  1. Change in Anti-Müllerian Hormone (AMH)

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum AMH level to assess ovarian reserve

  2. Change in Follicle-Stimulating Hormone (FSH)

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum FSH level

  3. Change in Estradiol

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum Estradiol level

  4. Change in Progesterone

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum Progesterone level

  5. Change in Testosterone

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum Testosterone level

  6. Change in 25-hydroxy Vitamin D

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum 25-hydroxy Vitamin D level

  7. Change in Serum Iron

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum iron level

  8. Change in Thyroid Stimulating Hormone (TSH)

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum TSH level

  9. Change in High-Sensitivity C-Reactive Protein (hs-CRP)

    Time frame: Baseline and Day 2-5 of Cycle 3

    Blood test measurement of serum hs-CRP level

Secondary outcomes

  1. Change in Self-Reported Reproductive Health

    Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

    Assessed via self-reported questionnaire measuring participant perceptions of reproductive health

  2. Change in Self-Reported Energy Levels

    Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

    Assessed via self-reported questionnaire measuring participant perceptions of energy levels

  3. Change in Self-Reported Mood

    Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

    Assessed via self-reported questionnaire measuring participant perceptions of mood

  4. Change in Self-Reported Breast Tenderness

    Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

    Assessed via self-reported questionnaire measuring participant perceptions of breast tenderness

  5. Change in Self-Reported Overall Well-Being

    Time frame: Baseline, Day 2-5 of Cycle 1, Day 2-5 of Cycle 2, and Day 2-5 of Cycle 3

    Assessed via self-reported questionnaire measuring participant perceptions of overall well-being

Sponsors and collaborators

Lead sponsor

WeNatal

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.